官方服务：
资源简介：
Sixteen approved NSCLC drugs.
应用场景：
创建时间：
2017-08-19
相关数据集
Pulmonary Drugs Market Size, Trends and Forecast to 2030
Pulmonary Drugs Market to be valued at $77.31 Bn by 2030. Report: Industry Size, Y-o-Y Growth Rate, Epidemiology, Prevalence Rate
www.coherentmarketinsights.com120
Fibroblast Activation Protein Inhibitors Market
Report of Fibroblast Activation Protein Inhibitors Market is currently supplying a comprehensive analysis of many things which are liable for economy growth and factors which could play an important p
IMR REPORTS60
Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites
Inhibitors targeting the epidermal growth factor receptor (EGFR) are an effective therapy for patients with non-small cell lung cancer harboring drug-sensitive activating mutations in the EGFR kinase
NIAID Data Ecosystem20
‘Effective’ drugs on SCLC cells.
*overlapping drug between two studies ‘Effective’ drugs on SCLC cells.
NIAID Data Ecosystem90
DataSheet_6_Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine.pdf
The impact of asparaginases on plasma asparagine and glutamine is well established. However, the effect of asparaginases, particularly those derived from Erwinia chrysanthemi (also called crisantaspas
NIAID Data Ecosystem40
